BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China

Reuters2024-12-20

BRIEF-<a href="https://laohu8.com/S/APLMW">Apollomics</a> Announces Results For Phase 3 Bridging Trial Of Uproleselan In China

Dec 20 (Reuters) - Apollomics Inc APLM.O:

APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING TRIAL OF UPROLESELAN IN CHINA IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
TRIAL DID NOT DEMONSTRATE FAVORABLE BENEFIT FOR UPROLESELAN
SERIOUS ADVERSE EVENTS 43% IN UPROLESELAN ARM VERSUS 39% IN CONTROL

Source text: ID:nGNX7xNhb

Further company coverage: APLM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492449236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492449236","market":"us","top_or_hot":-1,"title":"BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/APLMW\">Apollomics</a> Announces Results For Phase 3 Bridging Trial Of Uproleselan In China </title></head><body><p><span>Dec 20 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/APLM\">Apollomics Inc</a> <span>APLM.O</span>:</p><ul><li><p>APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING TRIAL OF UPROLESELAN IN CHINA IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA</p></li><li><p>TRIAL DID NOT DEMONSTRATE FAVORABLE BENEFIT FOR UPROLESELAN</p></li><li><p>SERIOUS ADVERSE EVENTS 43% IN UPROLESELAN ARM VERSUS 39% IN CONTROL</p></li></ul><p>Source text: <span>ID:nGNX7xNhb</span></p><p>Further company coverage: <span>APLM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA250VRW:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China Dec 20 (Reuters) - Apollomics Inc APLM.O:APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING TRIAL OF ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA250VRW:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLMW","symbol_name":"Apollomics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nTUA250VRW:1","article_id":"2492449236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492449236","pubTimestamp":1734704418,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China Dec 20 (Reuters) - Apollomics Inc APLM.O:APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING TRIAL OF UPROL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLMW":"Apollomics","BK4139":"生物科技","APLM":"Apollomics Inc"},"translate_title":"简介-Apollomics宣布Uproleselan在中国的3期桥接试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLM":0.9,"APLMW":0.9},"content_text":"BRIEF-Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China Dec 20 (Reuters) - Apollomics Inc APLM.O:APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING TRIAL OF UPROLESELAN IN CHINA IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIATRIAL DID NOT DEMONSTRATE FAVORABLE BENEFIT FOR UPROLESELANSERIOUS ADVERSE EVENTS 43% IN UPROLESELAN ARM VERSUS 39% IN CONTROLSource text: ID:nGNX7xNhbFurther company coverage: APLM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492449236"}